Viking Therapeutics, Inc. (ETR:1VT)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.97B -4.0% |
| Revenue (ttm) | n/a |
| Net Income | -468.11M |
| EPS | -4.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 158 |
| Open | 25.40 |
| Previous Close | 25.90 |
| Day's Range | 24.30 - 25.65 |
| 52-Week Range | 24.30 - 39.05 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 21, 2026 |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more]
News
Viking Therapeutics price target lowered to $85 from $87 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Viking Therapeutics (VKTX) to $85 from $87 and keeps a Buy rating on the shares as part of a broader…
Viking Therapeutics initiates oral maintenance dosing study of VK2735
Viking Therapeutics (VKTX) announced the initiation of an exploratory oral maintenance dosing study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinot...
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026...
3 Best Growth Stocks to Buy Now with 55%+ Upside, According to Analysts
Growth stocks can offer strong return potential when their businesses continue to expand. Viking Therapeutics ($VKTX), AeroVironment ($AVAV), and Ondas ($ONDS) stand out with Strong Buy ratings from a...
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the develo...
Viking Therapeutics falls -14.0%
Viking Therapeutics (VKTX) is down -14.0%, or -$5.82 to $35.83.
Viking Therapeutics falls -13.1%
Viking Therapeutics (VKTX) is down -13.1%, or -$5.46 to $36.19.
Viking Therapeutics 7.86M share Spot Secondary priced at $35.00
Morgan Stanley and JPMorgan are acting as joint book running managers for the offering. The deal size was increased to $225M from $200M and priced at the low end of…
Viking Therapeutics 7.857M share Spot Secondary priced at $35.00
The deal size was increased to $225M in common stock from $200M in common stock and priced at the low-end of the $35.00-$38.00 range. Morgan Stanley and JPMorgan acted as…
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine...
Viking Therapeutics $200M Spot Secondary; price range $35.00-$38.00
Morgan Stanley and JPMorgan are acting as joint book running managers for the offering.
Viking Therapeutics announces common stock, convertible senior notes offerings
Viking Therapeutics (VKTX) announced its intention to offer, subject to market and other conditions, $200M of common stock and $200M aggregate principal amount of convertible senior notes due 2032 in…
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine...
Viking Therapeutics price target raised to $87 from $83 at Truist
Truist raised the firm’s price target on Viking Therapeutics (VKTX) to $87 from $83 and keeps a Buy rating on the shares. The company’s VK2735 obesity data represents a “best-case…
Viking Therapeutics stock jumps 36% as weight loss drug shows lasting benefits with fewer doses
Viking Therapeutics ($VKTX) stock soared 35.67% on Tuesday after the company reported promising results from a study examining maintenance doses of its experimental weight loss shot, VK2735.
Can Viking Therapeutics stock retain today's gains?
Viking Therapeutics (VKTX) stock ripped higher on Tuesday morning after the biopharmaceutical company published promising clinical trial data. Investors rallied around new Phase 2 top-line results for...
Oppenheimer ups Viking Therapeutics target to $120 on ‘impressive’ data
Oppenheimer analyst Jay Olson raised the firm’s price target on Viking Therapeutics (VKTX) to $120 from $100 and keeps an Outperform rating on the shares. This morning’s VK2735 maintenance data…
Viking Therapeutics price target raised to $120 from $100 at Oppenheimer
Oppenheimer raised the firm’s price target on Viking Therapeutics (VKTX) to $120 from $100 and keeps an Outperform rating on the shares.
Viking Therapeutics rises 26.7%
Viking Therapeutics (VKTX) is up 26.7%, or $8.04 to $38.15.
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly's Zepbound. Its stock is soaring.
Viking Therapeutics Phase 1 data ‘highly encouraging,’ says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis calls Viking Therapeutics (VKTX)’ topline results from its Phase 1 VK2735-102 maintenance study “highly encouraging,” highlighting the strong induction efficac...
Viking Therapeutics obesity data ‘very positive,’ says Morgan Stanley
Morgan Stanley says Viking Therapeutics (VKTX)’ VK2735 data this morning are “very positive.” The 17.5 milligram dose showed a 22% placebo adjusted weight loss at 33 weeks following weekly dosing,…
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.
Viking Therapeutics Transcript: Study result
VK2735 demonstrated robust weight loss (up to 22% at 33 weeks) and high maintenance rates (up to 97%) with both every-other-week and monthly dosing, showing excellent tolerability comparable to placebo. Flexible, less frequent dosing regimens may improve adherence and persistence.
Viking Therapeutics Press release: Study result
Viking Therapeutics issued a press release on September 22, 2026, disclosing material business information to investors.